HC Wainwright Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price

Definium Therapeutics (NASDAQ:DFTX) had its price objective hoisted by investment analysts at HC Wainwright from $55.00 to $70.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 301.15% from the stock’s current price.

Several other brokerages have also issued reports on DFTX. JonesTrading started coverage on Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 target price for the company. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a report on Thursday, January 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a report on Monday, February 2nd. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a report on Monday, January 5th. Finally, Canaccord Genuity Group boosted their price target on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $35.70.

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock opened at $17.45 on Monday. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. Definium Therapeutics has a 52 week low of $4.70 and a 52 week high of $18.70. The company has a market cap of $1.72 billion, a PE ratio of -8.19 and a beta of 2.56. The business has a 50 day moving average of $15.66 and a 200 day moving average of $12.84.

Insider Buying and Selling

In other Definium Therapeutics news, insider Mark Sullivan sold 11,276 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This represents a 1.30% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 42,667 shares of company stock valued at $561,071. Corporate insiders own 2.26% of the company’s stock.

Institutional Trading of Definium Therapeutics

Large investors have recently made changes to their positions in the business. CenterBook Partners LP bought a new position in shares of Definium Therapeutics during the 3rd quarter valued at approximately $1,880,000. Marshall Wace LLP boosted its position in Definium Therapeutics by 31.9% in the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after buying an additional 828,067 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Definium Therapeutics by 4.0% in the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after purchasing an additional 66,663 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of Definium Therapeutics during the 2nd quarter worth $238,000. Finally, Stempoint Capital LP bought a new position in Definium Therapeutics during the 2nd quarter worth about $590,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.